ABSTRACT: Integrin α v β 3 is overexpressed in both neovasculature and glioma cells. We aimed to evaluate 68 gallium-BNOTA-PRGD2 ( 68 Ga-PRGD2) as a new reagent for noninvasive integrin α v β 3 imaging in glioma patients. With informed consent, 12 patients with suspicious brain glioma, as diagnosed by enhanced magnetic resonance imaging (MRI) scanning, were enrolled to undergo 68 Ga-PRGD2 PET/CT and 18 F-FDG PET/CT scans before surgery. The preoperative images were compared and correlated with the pathologically determined WHO grade. Next, the expression of integrin α v β 3 , CD34, and K i -67 were determined by immunohistochemical staining of the resected brain tumor tissue. Our findings demonstrated that 68 Ga-PRGD2 specifically accumulated in the brain tumors that were rich of integrin α v β 3 and other neovasculature markers, but not in the brain parenchyma other than the choroid plexus. Therefore, 68 Ga-PRGD2 PET/CT was able to evaluate the glioma demarcation more specifically than 18 F-FDG PET/CT. The maximum standardized uptake values (SUVmax) of 68 Ga-PRGD2, rather than those of 18 F-FDG, were significantly correlated with the glioma grading. The maximum tumor-to-brain ratios (TBRmax) of both tracers were significantly correlated with glioma grading, whereas 68 Ga-PRGD2 seemed to be more superior to 18 F-FDG in differentiating high-grade glioma (HGG) from low-grade glioma (LGG). Moreover, 68 Ga-PRGD2 PET/CT showed different accumulation patterns for HGG of WHO grades III and IV. This is the first noninvasive integrin imaging study, to the best of our knowledge, conducted in preoperative patients with different grades of glioma, and it preliminarily indicated the effectiveness of this novel method for evaluating glioma grading and demarcation.
■ INTRODUCTION
Gliomas are the most common malignant brain tumors, characterized by extensive, diffuse infiltrative growth into the surrounding brain parenchyma and different degrees of neovascularization. 1 Recent studies have demonstrated the diagnostic limitations of 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET). 2 The diagnostic accuracy of 18 F-FDG PET is weakened by high physiologic glucose metabolism in the brain areas where glioma is prone to occur, such as the cerebral cortex, basal ganglia, and thalamus. This significantly limited the sensitivity for glioma detection and the specificity for border demarcation. The uses of 11 Cmethionine and 18 F-fluorothymidine to image glioma showed better results but were still not enough for a final resolution. 3 Thus, there is a need to develop a more specific radiotracer for PET to assess glioma.
Several researchers have demonstrated that the expression of the integrins α v β 3 and α v β 5 , which are expressed in many glioma new-born vessels and glioma cells, generally increases with the grade of malignancy, and these integrins have been associated with poor prognosis, 4, 5 as replicated in a glioma animal model. 6 Basic research showed that integrins could drive glioma progression 7 and down-regulation of integrins or interference with integrin signaling pathways, which decreased migration and proliferation and improved survival in human glioblastoma cell lines. 8, 9 Cilengitide, an arginine-glycine-aspartic acid (RGD) pentapeptide integrin α v β 3 and α v β 5 inhibitor, was shown to improve glioblastoma multiforme (GBM, WHO grade IV) prognosis, based on preclinical and current clinical trials assessing angiogenesis, cell invasion, and migration, and it has been investigated in combination with standard therapy in several clinical trials in GBM patients. 10−14 Glioma is known to be a highly heterogeneous disease, particularly regarding intratumoral heterogeneity, which contributes in part to drug resistance for some receptor inhibitors. 15 Indeed, the premier research showed heterogeneous RGD uptake in GBM patients. 16 With the advent of personalized medicine, understanding of intratumoral heterogeneity at different levels has become mandatory for improving clinical outcomes. Noninvasive RGD PET/CT imaging represents a more promising approach than 18 F-FDG PET/ CT for the specific visualization of integrin α v β 3 in preoperative glioma patients or for locating residual postoperative glioma; furthermore, this technique could potentially provide appropriate therapeutic guidance for anti-integrin targeted therapy and antiangiogenesis therapy, as well.
Until now, there have been only a small number of studies using RGD molecular imaging, 6 ,17−20 including microPET studies, as well as studies using Tc-Galacto-RGD2, the tumor uptake of which was also in agreement with high integrin α v β 3 expression on glioma cells and in the neovasculature of nude mice bearing U87MG glioma xenografts. 21 Schnell et al. reported the first clinical research about 18 FGalacto-RGD PET/CT scans in GBM patients. 16 This study found that GBM demonstrated significant but heterogeneous RGD uptake, with the maximum uptake occurring in the highly proliferating and infiltrating areas of tumors, where α v β 3 expression was prominent in tumor microvessels, as well as in glial tumor cells. However, a limitation of this research was that it included not only newly diagnosed GBM but also recurrent GBM after external beam radiation or chemotherapy, thereby reducing its reliability.
In this prospective clinical study, we developed 68 gallium as a new positron emitter to label small RGD peptide antagonists of integrin α v β 3 , and we investigated this emitter in a prospective clinical cohort covering patients with different grades of newly diagnosed brain glioma. We hypothesized that the integrin α v β 3 expression shown in 68 gallium-BNOTA-PRGD2 ( 68 Ga-PRGD2) PET/CT scans could more precisely predict the preoperative glioma grading and could determine the demarcation more specifically than The inclusion criteria consisted of clinically based and magnetic resonance imaging (MRI)-based suspected newly diagnosed primary glioma; the patients were at least 18 years of age and had the ability to provide written and informed consent. The exclusion criteria were pregnancy, lactation, and inability to complete the needed examinations due to severe pain or claustrophobia. We evaluated all of the patients using preoperative brain 68 Ga-PRGD2 PET/CT and 18 F-FDG PET/ CT scans within 3 days. The pathology was determined by two neuropathologists separately, and they reached in consensus by referring a third pathologist when there was any discrepancy. The criteria of pathology diagnosis are the 2007 edition of WHO classification. 22 Low-grade glioma (LGG) includes grades I−II, and high-grade glioma (HGG) includes grades III−IV. This study was registered at www.clinicaltrials.gov under number NCT01801371. 18 F-FDG was produced on-site using Cyclotron RDS-111 (CTI, Knoxville, TN, USA). The same PET/CT system was used for scanning. Before the examinations, each patient was asked to fast for at least 4 h. The blood glucose levels of the patient were within normal limits (less than 6.4 mmol/L) before the 18 F-FDG was injected at a dosage of 5.55 MBq (0.15 mCi) per kilogram of body weight. The patients rested quietly in a warm and dark room for approximately 1 h. Subsequently, the patients underwent the examinations, using the same parameters that had been employed for the 68 Ga-PRGD2 PET/ CT scan.
Semiquantitative Analysis. Three experienced nuclear medicine physicians read all of the images through consensus reading. The same nuclear medicine physician examined and measured the semiquantitative values for the final analysis. A Siemens MMWP workstation was used for postprocessing. For each patient, the volume of interest (VOI) was drawn, and the maximum standardized uptake values (SUVmax) and maximum tumor-to-brain ratios (TBRmax) were recorded. TBRmax was obtained by dividing the SUVmax of the VOI by that of the unaffected contralateral brain.
Immunofluorescence and Immunohistochemical Analysis. We conducted the fluorescence staining to investigate integrin α v β 3 expression and immunohistochemical staining to see the angiogenesis of the patients and corroborated their PET/CT findings. . Cryosections (4-μm thick) were obtained and fixed in 95% ethanol for 10 min. Subsequently, 3% hydrogen peroxide (H 2 O 2 ) was added to quench endogenous peroxidase, and 10% goat serum (Zsgb Bio, Beijing, China) was used to block the remaining epitopes. Tissue slices were subsequently incubated at room temperature with one of the following monoclonal antibodies: CD34 (clone QBEnd/10, Leica Biosystems, Germany) at a dilution of 1:50 and K i -67 (clone EP5, Epitomics, USA) at a dilution of 1:100. The samples were incubated with homologous secondary antibodies conjugated with horseradish peroxidase (HRP) for 60 min and with diaminobenzidine (DAB) (K4065, DAKO, USA) at a dilution of 1:20 under microscopic examination. Finally, the sections were counterstained with hematoxylin.
Statistical Analysis. All of the data are expressed as means and standard deviation (SD). Spearman's correlation coefficient was calculated to assess the correlations between the SUVmax and TBRmax of 68 Ga-PRGD2 and the grading of the glioma. All of the statistical analyses were performed using GraphPad Prism software (version 5.01, GraphPad Software, Inc., Ca, USA), and p < 0.05 was considered to be statistically significant.
■ RESULTS Patient Characteristics. The inclusion criteria were fulfilled by 12 patients (2 women, 10 men) with a mean age of 43 ± 13 years (range, 23−66 years). All of the patients presented with short histories of clinical symptoms or with newly diagnosed neurological deficits underwent MRI with gadolinium-DTPA enhancement suggesting a diagnosis of glioma and were last confirmed as glioma by postoperative pathology. The tumors were located in one brain lobe in 2 patients, in two lobes in 7 patients, in three lobes in 1 patient, in the thalamus in 1 patient, and in the pons in 1 patient (Table  1) . Comparison of 68 Ga-PRGD2 and 18 F-FDG PET/CT Scans.
68 Ga-PRGD2 did not accumulate in normal brain tissue, including the white matter and cortical gray matter, with the exception of the choroid plexus. Therefore, it could determine the boundary of glioma, compared to the clean background in patients' brains ( Figure 1I,J) . In contrast, 18 F-FDG uptake in some HGG was less than that in normal gray matter. Thus, HGG lesions were defined as low FDG uptake areas, surrounded by the relatively high 18 F-FDG uptake of the normal brain tissue ( Figure 1N) . Therefore, 68 Ga-PRGD2 PET/CT scans had much higher sensitivity for detecting glioma and higher specificity for determining tumor demarcation, compared to 18 F-FDG PET/CT scans. The 68 Ga-PRGD2 accumulation pattern was different in grade III and IV glioma patients, compared with 18 F-FDG uptake. For anaplastic astrocytoma (grade III), the 68 Ga -PRGD2 expression had its own characteristic scattered focal area, resembling snowflakes ( Figure 1H ), while its uptake in GBM (grade IV) had much greater density, with a large bolus of PRGD2 accumulation ( Figure 1I ,J). In 18 F-FDG PET/CT, only the necrotic center without tracer uptake was a clue to identify grade IV glioma ( Figure 1N,O) , while the tracer accumulation in the solid components of grades III and IV glioma may be similar ( Figure 1M,N) . Therefore, the accumulation shape and density could be clues for differentiating grade III and IV gliomas, which have completely different prognoses.
Correlation of PET/CT Images with Glioma Grading. As shown in Table 2 , the SUVmax and TBRmax of Ga-PRGD2 and 18 F-FDG were both significantly correlated with the glioma grading (Table 2) . However, for differentiating the HGG from the LGG, 68 Ga-PRGD2 PET/CT reached 100% (8/8) sensitivity and 100% (4/4) specificity in this small group of patients when the threshold of TBRmax was set between 2.00 and 3.55, whereas the sensitivity, specificity, and accuracy of 18 F-FDG PET/CT were 88% (7/8), 75% (3/4), and 83% (10/12), respectively, with the TBRmax threshold setting between 1.30 and 1.31.
Histopathological Features and Immunohistochemical Staining of Resected Tumor Tissue. Tumor pathology determination of each of 11 patients' tumors was conducted on total resections or gross resections, whereas one patient missed the analysis because he received only stereotactic biopsy for the unresectable diffuse growth of the tumor.
We examined the histopathology and expression of integrin α v β 3 in the brain tumor tissue of 11 patients to corroborate the relevant findings with the 68 Ga-PRGD2 PET/CT findings. In agreement with the intense 68 Ga-PRGD2 accumulation in HGG (Figure 1 ), high levels of integrin α v β 3 receptor were selectively expressed on the tumor cells of HGG ( Figure 3B,F) , comparing to extremely low expression of integrin α v β 3 in LGG ( Figure 2D ). An extensive vascular network, with ongoing angiogenesis and proliferation, was observed in the HGG brain tumor tissue, as demonstrated by positive staining of CD34 ( Figure 3C,G) and K i -67 ( Figure 3D,H) .
■ DISCUSSION
Over the past decade, numerous studies have demonstrated that 18 F-FDG PET/CT is helpful for assessing glioma grading, determining the anaplastic transformation of LGG, differentiating recurrent glioma and radiation necrosis, and even predicting the survival of patients with recurrent glioma. 3,26−28 However, the sensitivity of glioma detection by 18 F-FDG PET/ LGG, low-grade glioma; HGG, high-grade glioma; r, correlation coefficient to the regarded WHO grading. *p < 0.05 was considered to be significant. CT is relatively low, particularly for LGG, because 18 F-FDG uptake in LGG is usually similar to that of normal white matter. Even in HGG, 18 F-FDG uptake varied greatly. 29 18 F-FDG uptake, by assessing only the mechanisms associated with elevated glucose metabolism, is nonspecific for the molecular characteristics of glioma.
68 Ga-PRGD2 was specifically designed to target the endothelial cells of the neovasculature and glioma cells that express integrin α v β 3 at high levels in glioma. We demonstrated the 68 Ga-PRGD2 PET/CT had higher sensitivity than 18 F-FDG due to the clear lack of 68 Ga-PRGD2 affinity of the normal brain.
SUVmax and TBR are both used to explain tumor PET/CT imaging, and they offer different advantages, with the former traditionally regarded as providing the representative value of each tumor. In this research, the SUVmax of 18 F-FDG was not correlated with glioma grading; one reason for this finding was that different patients' brains had different 18 F-FDG uptake backgrounds. In previous research, different regions of the brain have been used for reference uptake as the index of TBR in semiquantitative analysis, including white matter and unaffected contralateral gray matter. One study demonstrated that cutoff levels of 1.5 for the tumor-to-white matter (T/WM) FDG uptake ratio and 0.6 for the tumor-to-cortex (T/C) ratio were useful in the differentiation of LGG from HGG, with sensitivity of 94% and specificity of 77%. 28 However, TBRmax is more indicative of the most aggressive location in the tumor, and it can determine accurate grading for heterogeneous tumors. Additionally, it is easier and more reasonable to be used in clinical practice than the T/WM and T/C ratios because glioma can occur in both white matter and cortex, and it is sometimes difficult to distinguish the white matter and cortex on the CT images of PET/CT. Moreover, TBRmax has been increasingly used in new tracer PET/CT scans to assess glioma. 30−32 The TBRmax values of 18 F-FDG and 68 Ga-PRGD2 PET/CT were both significantly correlated with glioma grading, but the former could not differentiate LGG from HGG, and it showed some overlap between these two groups of values. Therefore, 68 Ga-PRGD2 PET/CT was superior to 18 F-FDG in distinguishing LGG from HGG.
To the best of our knowledge, this was the first study conducted in humans that investigated the use of integrin imaging (specifically 68 Ga-PRGD2 PET/CT) for preoperative, noninvasive assessment of glioma grading. We compared the findings of this technique with 18 F-FDG PET/CT findings from the same patients. We provided histopathological confirmation showing that the different levels of expression of integrin α v β 3 on glioma cells corresponded to the WHO glioma grading.
There are some limitations of the present study. First, the number of enrolled patients with glioma was small, especially in the lower grade group. However, each patient underwent 68 Ga-PRGD2 PET/CT and 18 F-FDG PET/CT scanning, and the preliminary results of this study support a pilot proof-ofconcept study. Second, the study lacked a sufficient number of control patients with other types of brain tumors. An additional study is required to recruit a broad variety of patients with brain-occupying lesions to determine the sensitivity, specificity, and accuracy of 68 Ga-PRGD2 PET/CT in assessing glioma. Studies with more cases are needed to correlate the imaging findings related to post-treatment changes with the clinical responses and final prognoses of patients with glioma.
In conclusion, this prospective clinical study demonstrated that 68 Ga-PRGD2 PET/CT is a specific method for identifying and assessing glioma neovasculature formation and glioma cells in patients with glioma. In contrast to 18 F-FDG PET/CT, 68 Ga-PRGD2 PET/CT is more specific for evaluating glioma demarcation. The SUVmax of 68 Ga-PRGD2 is significantly correlated with glioma grading, and the TBRmax of 68 Ga-PRGD2 is more superior to 18 F-FDG for differentiating HGG from LGG. Therefore, 68 Ga-PRGD2 PET/CT may be a useful tool for assessing glioma grading, demarcation, and neovasculature formation. Table 1 ; lower row E/F/G/H, patient no. 10 in Table 1 
